X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1819) 1819
Publication (78) 78
Book Review (31) 31
Book Chapter (6) 6
Dissertation (5) 5
Conference Proceeding (3) 3
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1005) 1005
humans (790) 790
sglt2 inhibitor (737) 737
type 2 diabetes (722) 722
diabetes (701) 701
glucose (617) 617
diabetes mellitus, type 2 - drug therapy (589) 589
sglt2 inhibitors (563) 563
dapagliflozin (550) 550
endocrinology & metabolism (522) 522
double-blind (444) 444
sodium-glucose transporter 2 - antagonists & inhibitors (444) 444
male (428) 428
hypoglycemic agents - therapeutic use (422) 422
sglt2 (385) 385
diabetes mellitus (354) 354
pharmacology & pharmacy (353) 353
dextrose (346) 346
female (329) 329
empagliflozin (325) 325
canagliflozin (320) 320
insulin (296) 296
animals (294) 294
glucosides - therapeutic use (293) 293
middle aged (279) 279
metformin (272) 272
sodium (257) 257
type 2 diabetes mellitus (256) 256
glycemic control (250) 250
hyperglycemia (246) 246
safety (235) 235
hypoglycemic agents - adverse effects (214) 214
type-2 diabetes-mellitus (210) 210
analysis (204) 204
hypoglycemic agents - pharmacology (202) 202
mellitus (202) 202
inadequate glycemic control (198) 198
adult (194) 194
benzhydryl compounds - therapeutic use (192) 192
care and treatment (192) 192
sodium-glucose transporter 2 - metabolism (192) 192
treatment outcome (192) 192
diabetes mellitus, type 2 - blood (190) 190
efficacy (187) 187
aged (180) 180
hypoglycemic agents (179) 179
drug therapy (177) 177
internal medicine (175) 175
glucosides - pharmacology (172) 172
blood glucose - drug effects (169) 169
clinical trials (169) 169
blood glucose - metabolism (165) 165
blood pressure (162) 162
glucosides - adverse effects (158) 158
diabetes therapy (157) 157
hypoglycemic agents - administration & dosage (152) 152
medicine & public health (145) 145
add-on (137) 137
diabetes mellitus, type 2 - metabolism (136) 136
blood-pressure (134) 134
heart failure (134) 134
double-blind method (133) 133
glucosides - administration & dosage (129) 129
hypoglycemia (127) 127
rats (127) 127
body weight (125) 125
risk factors (125) 125
diabetes mellitus, type 2 - complications (122) 122
medicine, general & internal (121) 121
inhibitors (118) 118
kidney (118) 118
inhibitor (116) 116
patients (116) 116
placebo-controlled trial (113) 113
drug therapy, combination (112) 112
cardiac & cardiovascular systems (111) 111
glucose metabolism (110) 110
benzhydryl compounds - pharmacology (108) 108
mortality (107) 107
pharmacokinetics (107) 107
review (106) 106
endocrinology (104) 104
glucose - metabolism (104) 104
benzhydryl compounds - adverse effects (103) 103
japanese patients (103) 103
research (103) 103
dose-response relationship, drug (102) 102
add-on therapy (101) 101
metabolism (101) 101
insulin resistance (98) 98
mice (96) 96
glycosylated hemoglobin (95) 95
cardiovascular disease (93) 93
kidney - metabolism (93) 93
glucose transporter (91) 91
risk (91) 91
benzhydryl compounds - administration & dosage (89) 89
hemoglobin (88) 88
monotherapy (88) 88
type-2 (88) 88
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1711) 1711
Japanese (28) 28
French (25) 25
German (17) 17
Spanish (14) 14
Czech (8) 8
Chinese (7) 7
Russian (7) 7
Korean (4) 4
Slovak (4) 4
Polish (3) 3
Arabic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2018, Volume 20, Issue 11, pp. 2585 - 2597
Aims: Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of type 2 diabetes mellitus (T2DM); some SGLT2i have reported... 
SGLT2 inhibitor | type 2 diabetes | ENDOCRINOLOGY & METABOLISM | Humans | Middle Aged | Observational Studies as Topic - statistics & numerical data | Hospitalization - statistics & numerical data | Male | Diabetes Mellitus, Type 2 - epidemiology | Heart Failure - prevention & control | Young Adult | Canagliflozin - therapeutic use | Aged, 80 and over | Adult | Female | Databases as Topic - statistics & numerical data | Retrospective Studies | Diabetic Angiopathies - prevention & control | Heart Failure - epidemiology | Heart Failure - etiology | Diabetes Mellitus, Type 2 - complications | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Diabetic Foot - prevention & control | Risk Factors | Diabetic Foot - surgery | Diabetic Foot - etiology | Treatment Outcome | Diabetic Angiopathies - therapy | Diabetic Foot - epidemiology | Adolescent | Diabetic Angiopathies - epidemiology | Aged | Amputation - statistics & numerical data | Diabetes Mellitus, Type 2 - drug therapy | Heart failure | Type 2 diabetes | Medical research | Databases | Amputation | Medicine, Experimental | Comparative analysis | Risk factors | Knee | Glucose transporter | Diabetes mellitus | Clinical trials | Cardiovascular disease | Patients | Data bases | Sodium | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Heart diseases | Original
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2013, Volume 15, Issue 12, pp. 1154 - 1160
Journal Article
Journal Article
Kidney International, ISSN 0085-2538, 07/2018, Volume 94, Issue 1, pp. 26 - 39
Over the past two years, our understanding of anti-hyperglycemic medications used to treat patients with type 2 diabetes (T2D) has fundamentally changed.... 
diabetic kidney disease | albuminuria | blood pressure | heart failure | inflammation | SGLT2 inhibition | cardiovascular | SELECTIVE SGLT2 INHIBITOR | TRANSIENT ISCHEMIC ATTACK | HEART-FAILURE | SERUM URIC-ACID | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | PLACEBO-CONTROLLED TRIAL | CHRONIC KIDNEY-DISEASE | TYPE-2 DIABETES-MELLITUS | POST-HOC ANALYSIS | REG OUTCOME TRIAL | Diabetic Nephropathies - etiology | Cardiovascular Diseases - prevention & control | Humans | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Hospitalization - statistics & numerical data | Diabetic Nephropathies - blood | Protective Agents - therapeutic use | Sodium - metabolism | Kidney - metabolism | Sodium - urine | Protective Agents - pharmacology | Cardiovascular Diseases - blood | Cardiovascular Diseases - mortality | Glucosides - therapeutic use | Benzhydryl Compounds - therapeutic use | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Glucosides - pharmacology | Kidney - drug effects | Sodium-Glucose Transporter 2 - metabolism | Renal Elimination - drug effects | Treatment Outcome | Clinical Trials as Topic | Disease Progression | Sodium - blood | Diabetic Nephropathies - mortality | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Benzhydryl Compounds - pharmacology | Diabetes Mellitus, Type 2 - drug therapy
Journal Article
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2018, Volume 20, Issue 5, pp. 1111 - 1120
Aim: To evaluate the efficacy and safety of ertugliflozin and sitagliptin co-administration vs the individual agents in patients with type 2 diabetes who are... 
clinical trial | phase | study | type 2 diabetes | DPP‐IV | inhibitor | SGLT2 | III | glycaemic control | SGLT2 inhibitor | phase III study | DPP-IV inhibitor | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | MONOTHERAPY | EFFICACY | SAFETY | COMBINATION | BLOOD-PRESSURE | GLUCOSE COTRANSPORTER 2 | THERAPY | ENDOCRINOLOGY & METABOLISM | EMPAGLIFLOZIN | Glycated Hemoglobin A - analysis | Overweight - complications | Metformin - therapeutic use | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Drug Therapy, Combination - adverse effects | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - administration & dosage | Female | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Double-Blind Method | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Diabetes Mellitus, Type 2 - blood | Sitagliptin Phosphate - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Sitagliptin Phosphate - adverse effects | Hypertension | Type 2 diabetes | Medical research | Care and treatment | Body weight | Clinical trials | Glycosylated hemoglobin | Mycoses | Complications and side effects | Analysis | Medicine, Experimental | Urinary tract infections | Hypoglycemic agents | Diabetes therapy | Diabetes mellitus | Hemoglobin | Blood pressure | Urinary tract | Diabetes | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent) | DPP‐IV inhibitor | Original
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2018, Volume 20, Issue 12, pp. 2792 - 2799
Journal Article